A study of NUC-7738 for the treatment of solid cancers or lymphoma
Research type
Research Study
Full title
A two-part, Phase I, open-label, dose-escalation and expansion study to assess the safety, pharmacokinetics and clinical activity of NUC-7738, a nucleotide analogue, in patients with advanced solid tumours or lymphoma
IRAS ID
253656
Contact name
Sarah Blagden
Contact email
Sponsor organisation
NuCana, plc
Eudract number
2018-003417-17
Duration of Study in the UK
2 years, 8 months, 14 days
Research summary
This is a research study to test a new investigational drug called NUC-7738. NUC-7738 belongs to a new class of anti-cancer agents called ProTides that are specifically designed to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
The primary objective of this study is to investigate the safety and tolerability of NUC-7738 in subjects with solid tumours or lymphomas. This is a first-in-man study.
The study is funded by NuCANA plc, an Edinburgh based company. Subjects who have solid tumours or lymphomas will be recruited from 3 hospitals in the UK. These subjects will receive the investigational drug in small groups at escalating doses in order to find the safest dose tolerated.
The study will last for around 2 years and subjects will be in the study for approx 7 months.REC name
South Central - Oxford C Research Ethics Committee
REC reference
18/SC/0628
Date of REC Opinion
24 Dec 2018
REC opinion
Further Information Favourable Opinion